Clause 262 is a proposed amendment to enable the National Research Council to manufacture and produce medical products such as vaccines on a larger scale to respond to pandemics and other public health needs.
Currently, the NRC is authorized to produce medical products on a smaller scale for things like clinical trials and experiments. This new authority would provide the NRC with the ability to manufacture vaccines at a larger scale once the new biologics manufacturing centre at the Royalmount campus in Montreal receives regulatory approval by Health Canada.